Recurrence of in-stent restenosis in cardiac allograft vasculopathy following implantation of a sirolimus-eluting stent

Transplant International

Volumn 18, Issue 9, 2005, Pages 1113-1115

  Wessely, Rainer ^a,b   Pache, Jürgen ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cardiac allograft vasculopathy; Drug eluting stent; Heart transplantation; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; AZATHIOPRINE; BISOPROLOL; CLOPIDOGREL; CYCLOSPORIN A; FUROSEMIDE; HYDROCHLOROTHIAZIDE; PRAVASTATIN; RAPAMYCIN; VALSARTAN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CASE REPORT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; IMPLANTATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RECURRENCE RISK; RESTENOSIS; TREATMENT OUTCOME; ALLOTRANSPLANTATION; MIDDLE AGED; RECURRENT DISEASE; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SIROLIMUS; STENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 26944483561     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00188.x     Document Type: Article

References (18)

1. Weis M, von Scheldt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96: 2069.
2. Escobar A, Ventura HO, Stapleton DD, et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1994; 74: 1042.
3. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
4. Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart transplant vasculopathy. Transplantation 2003; 76: 1470.
5. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998; 17: 744.
6. Benza RL, Zoghbi GJ, Tallaj J, et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol 2004; 43: 1973.
7. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315.
8. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221.
9. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587.
10. Lemos PA, van Mieghem CAG, Arampatzis CA, et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes. Circulation 2004; 109: 2500.
11. Avery RK. Cardiac-allograft vasculopathy. N Engl J Med 2003; 349: 829.
12. Schnetzler B, Drobinski G, Dorent R, et al. The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant 2000; 19: 557.
13. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent placement and ballon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 17: 758.
14. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 2003; 41: 184.
15. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. Jama 2005; 293: 165.
16. Colombo A, Orlic D, Stankovic G, et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003; 107: 2178.
17. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48.
18. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.